Drug name - Vyvanse
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7659253 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(4 months from now) | |
| US7655630 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(4 months from now) | |
| US7662787 | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Feb, 2023
(4 months from now) | |
| CN1747737A | TAKEDA PHARMS USA | Saccharide Conjugates Prevent Abuse Of The Control Medicine |
Sep, 2011
(11 years ago) | |
| CN101193650A | TAKEDA PHARMS USA | Abuse-Resistance Amphetamine Prodrugs |
Dec, 2012
(9 years ago) | |
| CN1476325A | TAKEDA PHARMS USA | Conveying System And Method Of Protecting And Administering Active Material Active Material |
Oct, 2015
(6 years ago) | |
| CN1476325B | TAKEDA PHARMS USA | Active Agent Delivery Systems And Methods For Protecting And Administering Active Agents |
Oct, 2015
(6 years ago) | |
| CN100413533C | TAKEDA PHARMS USA | A Pharmaceutical Compound For Preventing Sustained Release Of Control Of Substance Abuse |
Feb, 2022
(7 months ago) | |
| CN1720059A | TAKEDA PHARMS USA | Sustained Release Model Of Preventing Substance Abuse Of A Pharmaceutical Compound |
Feb, 2022
(7 months ago) | |
| CN1816346A | TAKEDA PHARMS USA | Abuse Resistant Amphetamine Compounds |
Jun, 2024
(1 year, 7 months from now) | |
| CN1816346B | TAKEDA PHARMS USA | Abuse Resistant Amphetamine Compounds |
Jun, 2024
(1 year, 7 months from now) | |
| CN1925865B | TAKEDA PHARMS USA | Pharmaceutical Composition Of Preventing Overdose Or Abuse |
Sep, 2024
(1 year, 11 months from now) | |
| CN1925865A | TAKEDA PHARMS USA | Pharmaceutical Compositions For Prevention Of Overdose Or Abuse |
Sep, 2024
(1 year, 11 months from now) | |
| IN200401300P2 | TAKEDA PHARMS USA | Novel Sustained Release Pharmaceutical Compounds To Prevent Abuse Of Controlled Substances |
Feb, 2023
(4 months from now) | |
| IN231459B | TAKEDA PHARMS USA | Novel Sustained Release Pharmaceutical Compounds To Prevent Abuse Of Controlled Substances |
Feb, 2023
(4 months from now) | |
| IN250464B | TAKEDA PHARMS USA | Abuse Resistant Amphetamine Compounds |
Jun, 2024
(1 year, 7 months from now) | |
| IN200502683P2 | TAKEDA PHARMS USA | Abuse Resistant Amphetamine Compounds Cross Reference Related Applications |
Jun, 2024
(1 year, 7 months from now) | |
| EP1311242A4 | TAKEDA PHARMS USA | Active Agent Delivery Systems And Methods For Protecting And Administering Active Agents |
Aug, 2021
(1 year, 1 month ago) | |
| EP1311242B1 | TAKEDA PHARMS USA | Active Agent Delivery Systems And Methods For Protecting And Administering Active Agents |
Aug, 2021
(1 year, 1 month ago) | |
| EP1311242A1 | TAKEDA PHARMS USA | Active Agent Delivery Systems And Methods For Protecting And Administering Active Agents |
Aug, 2021
(1 year, 1 month ago) | |
| EP1401374A1 | TAKEDA PHARMS USA | A Novel Pharmaceutical Compound Containing Atenolol And Methods Of Making And Using Same |
Nov, 2021
(10 months ago) | |
| EP1401374B1 | TAKEDA PHARMS USA | A Novel Pharmaceutical Compound Containing Atenolol And Methods Of Making And Using Same |
Nov, 2021
(10 months ago) | |
| EP1401374A4 | TAKEDA PHARMS USA | A Novel Pharmaceutical Compound Containing Abacavir Sulfate And Methods Of Making And Using Same |
Nov, 2021
(10 months ago) | |
| EP1357928A2 | TAKEDA PHARMS USA | A Novel Pharmaceutical Compound And Methods Of Making And Using Same |
Nov, 2021
(10 months ago) | |
| EP1357928B1 | TAKEDA PHARMS USA | A Novel Pharmaceutical Compound And Methods Of Making And Using Same |
Nov, 2021
(10 months ago) | |
| EP1357928A4 | TAKEDA PHARMS USA | A Novel Pharmaceutical Compound And Methods Of Making And Using Same |
Nov, 2021
(10 months ago) | |
| EP1531844A4 | TAKEDA PHARMS USA | Novel Sustained Release Pharmaceutical Compounds To Prevent Abuse Of Controlled Substances |
Feb, 2023
(4 months from now) | |
| EP1531844A2 | TAKEDA PHARMS USA | Novel Sustained Release Pharmaceutical Compounds To Prevent Abuse Of Controlled Substances |
Feb, 2023
(4 months from now) | |
| EP1531844B1 | TAKEDA PHARMS USA | Novel Sustained Release Pharmaceutical Compounds To Prevent Abuse Of Controlled Substances |
Feb, 2023
(4 months from now) | |
| EP1594513B1 | TAKEDA PHARMS USA | Carbohydrate Conjugates To Prevent Abuse Of Controlled Substances |
Jan, 2024
(1 year, 3 months from now) | |
| EP1594513A4 | TAKEDA PHARMS USA | Carbohydrate Conjugates To Prevent Abuse Of Controlled Substances |
Jan, 2024
(1 year, 3 months from now) | |
| EP1594513A2 | TAKEDA PHARMS USA | Carbohydrate Conjugates To Prevent Abuse Of Controlled Substances |
Jan, 2024
(1 year, 3 months from now) | |
| EP1644019A1 | TAKEDA PHARMS USA | Abuse Resistant Amphetamine Compounds |
Jun, 2024
(1 year, 7 months from now) | |
| EP1644019A4 | TAKEDA PHARMS USA | Abuse Resistant Amphetamine Compounds |
Jun, 2024
(1 year, 7 months from now) | |
| EP1644019B1 | TAKEDA PHARMS USA | Abuse Resistant Amphetamine Compounds |
Jun, 2024
(1 year, 7 months from now) | |
| EP1644019B2 | TAKEDA PHARMS USA | Abuse Resistant Amphetamine Compounds |
Jun, 2024
(1 year, 7 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7687466 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(4 months from now) | |
| US7723305 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(4 months from now) | |
| US7678771 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(4 months from now) | |
| US7674774 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(4 months from now) | |
| US7662788 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(4 months from now) | |
| US7105486 | TAKEDA PHARMS USA | Abuse-resistant amphetamine compounds |
Feb, 2023
(4 months from now) | |
| US7659254 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(4 months from now) | |
| US7671031 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(4 months from now) | |
| US7671030 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(4 months from now) | |
| US7687467 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(4 months from now) | |
| US7678770 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(4 months from now) | |
| US7718619 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(4 months from now) | |
| US7223735 | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Feb, 2023
(4 months from now) | |
| US7713936 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(4 months from now) | |
| US7700561 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(4 months from now) | |
|
US7223735
(Pediatric) | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Aug, 2023
(10 months from now) | |
|
US7655630
(Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(10 months from now) | |
|
US7659253
(Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(10 months from now) | |
|
US7662788
(Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(10 months from now) | |
|
US7662787
(Pediatric) | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Aug, 2023
(10 months from now) | |
|
US7659254
(Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(10 months from now) | |
|
US7671030
(Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(10 months from now) | |
|
US7671031
(Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(10 months from now) | |
|
US7674774
(Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(10 months from now) | |
|
US7678770
(Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(10 months from now) | |
|
US7678771
(Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(10 months from now) | |
|
US7687466
(Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(10 months from now) | |
|
US7687467
(Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(10 months from now) | |
|
US7713936
(Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(10 months from now) | |
|
US7700561
(Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(10 months from now) | |
|
US7105486
(Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine compounds |
Aug, 2023
(10 months from now) | |
|
US7723305
(Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(10 months from now) | |
|
US7718619
(Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(10 months from now) | |
Drugs and Companies using LISDEXAMFETAMINE DIMESYLATE ingredient
Treatment: Indicated for the treatment of attention-deficit/hyperactivity disorder (adhd); For the treatment of attention deficit hyperactivity disorder (adhd); For the treatment of attention deficit hyperactivity disorder (adhd); indicated for the treatment of attention-deficit/hyperactivity disorder (adhd); Treatment of attention deficit hyperactivity disorder (adhd) in adults
Dosage: TABLET, CHEWABLE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 10MG | TABLET, CHEWABLE;ORAL | Prescription |
| 20MG | TABLET, CHEWABLE;ORAL | Prescription |
| 30MG | TABLET, CHEWABLE;ORAL | Prescription |
| 40MG | TABLET, CHEWABLE;ORAL | Prescription |
| 50MG | TABLET, CHEWABLE;ORAL | Prescription |
| 60MG | TABLET, CHEWABLE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.